Patterns of care in the management of seminoma stage I: Results from a European survey

BJU International

Volumn 110, Issue 4, 2012, Pages 524-531

  Vossen, Carla Y ^a,b   Horwich, Alan ^c   Daugaard, Gedske ^d   Van Poppel, Hein ^e   Osanto, Susanne ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d University of Copenhagen   (Denmark)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

orchidectomy; physicians; population surveillance; questionnaires; seminoma; testicular neoplasms

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; EUROPE; HUMAN; ONCOLOGIST; ORCHIECTOMY; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOLOGIST; SEMINOMA; UROLOGIST;

COMBINED MODALITY THERAPY; EUROPE; HUMANS; MALE; MEDICAL ONCOLOGY; MEDICAL STAFF, HOSPITAL; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PHYSICIAN'S PRACTICE PATTERNS; POSTOPERATIVE CARE; RADIOLOGY; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; UROLOGY;

EID: 84864445837     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10887.x     Document Type: Article

References (25)

1. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, Mcglynn KA,. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev 2010; 19: 1151-9
2. Tandstad T, Smaaland R, Solberg A, et al,. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. J Clin Oncol 2011; 29: 719-25
3. Horwich A, Shipley J, Huddart R,. Testicular germ-cell cancer. Lancet 2006; 367: 754-65 (Pubitemid 43326294)
4. Krege S, Beyer J, Souchon R, et al,. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: a report of The Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I. Eur Urol 2008; 53: 478-96
5. Huddart RA, Norman A, Shahidi M, et al,. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-23 (Pubitemid 46594104)
6. Travis LB, Fossa SD, Schonfeld SJ, et al,. Second cancers among 40 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97: 1354-65 (Pubitemid 41487803)
7. Van Den Belt-Dusebout AW, De Wit R, Gietema JA, et al,. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25: 4370-8 (Pubitemid 350013842)
8. Haugnes HS, Wethal T, Aass N, et al,. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28: 4649-57
9. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C,. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 1992; 65: 775-8
10. Daugaard G, Petersen PM, Rorth M,. Surveillance in stage I testicular cancer. APMIS 2003; 111: 76-83
11. Cummins S, Yau T, Huddart R, Dearnaley D, Horwich A,. Surveillance in stage I seminoma patients: a long-term assessment. Eur Urol 2010; 57: 673-8
12. Oliver RT, Mason MD, Mead GM, et al,. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366: 293-300 (Pubitemid 41019418)
13. Mead GM, Fossa SD, Oliver RT, et al,. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 2011; 103: 241-9
14. Warde P, Jewett MA,. Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 1998; 25: 425-33 (Pubitemid 28384607)
15. Horwich A,. Stage I seminoma and carboplatin risks. Ann Oncol 2008; 19: 407-8 (Pubitemid 351325658)
16. Lawrentschuk N, Fleshner N,. Clinical stage I seminoma: the case for surveillance. World J Urol 2009; 27: 433-9
17. Feldman DR, Bosl GJ,. Treatment of stage I seminoma: is it time to change your practice? J Hematol Oncol 2008; 1: 22
18. Jones WG, Fossa SD, Mead GM, et al,. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation For The Research And Treatment Of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 2005; 23: 1200-8 (Pubitemid 46202277)
19. Choo R, Thomas G, Woo T, et al,. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005; 61: 736-40 (Pubitemid 40247967)
20. Warde P, Specht L, Horwich A, et al,. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 20: 4448-52 (Pubitemid 35334756)
21. Chung PW, Daugaard G, Tyldesley S, et al,. Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol 2010; 28: Suppl; Abstr 4535
22. Alomary I, Samant R, Genest P, Eapen L, Gallant V,. The preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol (R Coll Radiol) 2006; 18: 696-9 (Pubitemid 44464041)
23. Chung P, Mayhew LA, Warde P, Winquist E, Lukka H,. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol) 2010; 22: 6-16
24. Vandenbroucke JP,. What is the best evidence for determining harms of medical treatment? CMAJ 2006; 174: 645-6 (Pubitemid 43341875)
25. Vandenbroucke JP,. Observational research, randomised trials, and two views of medical science. PLoS Med 2008; 5: E67